Epilepsy

Neurology News Network for the week ending July 2, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 2, 2021.

The grant will fund a new study to evaluate the effectiveness of brain-responsive neuromodulation in patients with LGS. The study is expected to begin accepting patients in the second half of 2022.

The SUDEP-3 outperformed the prior SUDEP-7 variation on all measures, and simplifies the risk assessment with a 3-item weighted scoring while enhancing the clinical practicality.

Considerations of genetic testing regarding family planning as well as behavioral issues associated with Dravet syndrome.

The clinical fellow at Massachusetts General Hospital discussed his approach to highlighting flaws within the medical education system and the need to do so for certain areas in epilepsy.

Elaine C. Wirrell, MD, explains the increased risk of sudden unexpected death in epilepsy (SUDEP) in patients with Dravet syndrome and how to talk about it with caregivers and families.

An excellent epilepsy outcome was achieved in 66% of cases over a median follow-up of 41 months and was not significantly associated with the type of surgery undergone.

Here's what is coming soon to NeurologyLive.

We kindly ask you to share 5 minutes of your time with us in order to help us better understand how you use social media and how we can better serve you across different platforms.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 25, 2021.

Elaine Wirrell, MD, provides background on fenfluramine, results from 2 clinical trials, and compares it to other treatment therapies.

Elizabeth Thiele, MD, PhD, reviews cannabidiol oral solution as treatment of seizures associated with Dravet syndrome and the safety profile and dosing associated with it.

Calli L. Cook, NP, DNP, nurse practitioner, Woodruff School of Nursing, Emory University, detailed her vision for creating change within the neurology field by incorporating advanced practice clinicians.

The clinical fellow at Massachusetts General Hospital discussed the basis of his study evaluating adult neurology trainees and their familiarity with SUDEP and its risks.

The importance of early diagnosis of Dravet syndrome as well as seizure triggers and comorbidities are discussed by key opinion leaders in the field.

Joseph Sullivan, MD, and Elaine C. Wirrell, MD, discuss the presentation of Dravet syndrome in children.

Here's what is coming soon to NeurologyLive.

About half of national (49%) and international trainees rarely or never counseled patients on sudden death in epilepsy, despite the majority reporting seeing at least 45 patients with the condition during their training.

Neurology News Network for the week ending June 19, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 18, 2021.

Experts in the field discuss second- and third-line treatment options for Dravet syndrome such as stiripentol and vagal nerve stimulation and the effects they’ve seen on patients.

With new formulations of effective seizure rescue medications available, epilepsy specialists have begun to refine the approach and education to treating these emergency situations.

A panel discussion on the North American Consensus statement on treating Dravet syndrome and the approved therapies like clobazam, ketogenic diets, and other first- and second-line therapies.

Elizabeth Thiele, MD, PhD, and Peter Crino, MD, PhD, provide closing remarks on the future treatment landscape of tuberous sclerosis complex.